🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in India / NCT06042127
Recruiting Not applicable

POEM-F for Achalasia International Study

NCT06042127 · tracked via the Priya Life Science India tracker
Sponsor
Chinese University of Hong Kong
Phase
Not applicable
Started
2023-12-01
Last updated
2024-12-03

Condition(s) studied

Achalasia

Investigational drug(s) / intervention(s)

POEM-FConventional POEM

POEM-F: POEM-F would be performed as described in the arms section

Conventional POEM: Anterior POEM performed as described in the arms section

Study summary

Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in up to 50-60% of patients. In order to reduce the risk of GERD, endoscopic fundoplication has been developed as a novel procedure mimicking surgical anterior partial fundoplication that can be performed in the same session as POEM (POEM-F). Case series of POEM-F in patients with achalasia reported encouraging outcomes of low GERD rate of \~12% at 1 year. Prospective comparative data between POEM-F and conventional POEM on post-procedure GERD is current lacking. The investigators therefore designed an international multicenter prospective randomized study to investigate the efficacy of POEM-F. The investigators postulate that POEM-F could reduce the incidence of post-procedure GERD when compared with conventional POEM.

This is an international multicenter randomized controlled trial conducted between high volume expert centers from Hong Kong SAR, China, India and United States of America. Adult patients with manometry confirmed achalasia would be randomised to undergo POEM-F or POEM. The procedure would be performed by experts with vast experience in POEM. The primary outcome is the incidence of post-procedure GERD at 1 year, defined by the updated Lyon consensus. Secondary outcomes include technical and clinical success rates, adverse events, post-POEM endoscopic and manometry findings as well as patients' symptom scores.

Sample size calculation Based on existing pilot comparative data on POEM-F and POEM, it is estimated that 84 patients would be required to demonstrate a difference in post-procedure GERD of 47.6% to 18.2%, with 80% power and false positive rate of 0.05, accounting for 10% loss to follow-up.

Purpose and potential The current study proposal could demonstrate the superiority of POEM-F over POEM in reducing post-procedural GERD. It would also demonstrate the safety and reproducibility of the technique in expert centers across the globe. It could potentially replace conventional POEM as the preferred minimally invasive endoscopic treatment for achalasia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion criteria: 1. Adult patient (age ≥18 and ≤65 years-old) and with symptomatic achalasia type I or II. 2. Capability of understanding and complying with the study requirements, including filling the Eckardt Score, GERD-HRQL and RSI questionnaire and signing the informed consent form. 3. Patients with achalasia type I, II or III who are one of the following: * Treatment naïve, or * Failed prior through-the-scope balloon dilation, Savary or pneumatic dilation Exclusion criteria: 1. Patients unable or unwilling to provide consent. 2. Previous esophageal or gastric surgery. 3. Prior achalasia treatment including Heller myotomy, POEM. 4. Sigmoid achalasia, or significant esophageal dilatation \>6cm in lower esophagus 5. Disrupted mucosal integrity at the distal esophagus, eg. Ulcer, fibrotic scars etc 6. Patients with large hiatal hernias (axial length \> 2 cm and Hill grade \>2). 7. Patients with significant cardiorespiratory comorbidities which may limit their ability to undertake general anesthesia for the procedure, including ASA grade III or above. 8. Patients with obesity (Body Mass Index (BMI) ≥ 30). 9. Pregnant women or those planning pregnancy or breastfeeding women. 10. Uncorrectable coagulopathy defined by international normalized ratio (INR) \> 1.5 or platelet count \< 50000/µl.

Primary outcome measure(s)

Trial sites (7)

FacilityCityRegionStatus
Johns Hopkins Hospital Baltimore Maryland Not Yet Recruiting
Nanfang Hospital, Southern Medical University Guangzhou China Not Yet Recruiting
The Chinese University of Hong Kong Hong Kong Hong Kong Recruiting
Post Graduate Institute of Medical Education and Research Chandigarh India Not Yet Recruiting
Asian Institute of Gastroenterology Hyderabad India Not Yet Recruiting
Baldota Institute of Digestive Sciences Mumbai India Not Yet Recruiting
Deenanath Mangeshkar Hospital & Research Center Pune India Not Yet Recruiting

More Chinese University of Hong Kong trials in India

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06042127 on ClinicalTrials.gov ↗ ← All trials in India